2-(2,6-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid benzyl-N-methylamide | 667905-45-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-(2,6-dichlorophenylamino)-4-trifluoromethylpyrimidine-5-carboxylic acid benzyl-N-methylamide
• 英文别名: N-benzyl-2-(2,6-dichloroanilino)-N-methyl-4-(trifluoromethyl)pyrimidine-5-carboxamide
• CAS: 667905-45-5
• 化学式: C₂₀H₁₅Cl₂F₃N₄O
• 分子量: 455.267
• InChiKey: WVZYJBMVGCEXGZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  58.1
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• [EN] PYRIMIDINE COMPOUNDS<br/>[FR] COMPOSES DE PYRIMIDINE
  申请人：GLAXO GROUP LTD

  公开号：WO2004018434A1

  公开（公告）日：2004-03-04

  The present invention relates to novel pyrimidine derivatives, pharmaceutical compositions containing these compounds and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease in activity of the cannabinoid receptor.

  本发明涉及新型嘧啶衍生物、含有这些化合物的药物组合物以及它们在治疗疾病中的应用，尤其是治疗由于大麻素受体活性的增加或减少而直接或间接引起的疼痛等疾病。
• Pyrimidine compounds
  申请人：Eatherton John Andrew

  公开号：US20060247261A1

  公开（公告）日：2006-11-02

  The present invention relates to novel pyrimidine derivatives, pharmaceutical compositions containing these compounds and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease in activity of the cannabinoid receptor.

  本发明涉及新型嘧啶衍生物，包含这些化合物的药物组合物以及它们在治疗疾病，特别是由于大麻素受体活性的增加或减少而直接或间接引起疾病，尤其是疼痛方面的应用。
• Combination Of Cb2 Modulators And Pde4 Inhibitors For Use In Medicine
  申请人：Brown Andrew James

  公开号：US20080132505A1

  公开（公告）日：2008-06-05

  Combination of one or more CB2 modulators and one or more PDE4 inhibitors, and method of treating conditions which are mediated by the activity of CB2 receptors or conditions which are mediated by PDE4.

  一种由一种或多种CB2调节剂和一种或多种PDE4抑制剂组合而成的治疗方法，用于治疗由CB2受体活性介导的疾病或由PDE4介导的疾病。
• Pyrimidine derivatives as CB2 cannabinoid receptor modulators
  申请人：GLAXO GROUP LIMITED

  公开号：EP1736470A2

  公开（公告）日：2006-12-27

  The present invention relates to novel pyrimidine derivatives, pharmaceutical compositions containing these compounds and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease in activity of the cannabinoid receptor.

  本发明涉及新型嘧啶衍生物、含有这些化合物的药物组合物及其在治疗疾病（尤其是疼痛）中的用途，这些疾病是由大麻素受体活性的增加或降低直接或间接引起的。
• PYRIMIDINE COMPOUNDS
  申请人：GLAXO GROUP LIMITED

  公开号：EP1534687A1

  公开（公告）日：2005-06-01